BioMarin (BMRN) Stock: The Patent Fight Is Over and BioMarin Won Royalties

TLDR

• BioMarin and Ascendis Pharma reached a global settlement resolving all patent disputes over Ascendis’s drug Yuviwel.
• Ascendis will pay BioMarin a 20% royalty on U.S. net sales and 18% on sales in the EU, Brazil, and South Korea.
• Royalty payments are retroactive to Yuviwel’s first commercial sale and run until May 2030.
• The deal covers all current and potential indications for Yuviwel, including achondroplasia and hypochondroplasia.
• BioMarin will drop its Section 337 investigation at the ITC and dismiss related litigation across multiple countries.

BioMarin Pharmaceutical (BMRN) reached a global patent settlement with Ascendis Pharma on August 30, 2026, ending a legal battle over CNP technology used in Ascendis’s drug Yuviwel. BMRN stock was down 0.96% around the time of the announcement.

BioMarin Pharmaceutical Inc., BMRN

The two companies had been locked in disputes across multiple jurisdictions, including proceedings before the U.S. International Trade Commission. The settlement wraps up all of that in one agreement.

… Continue reading the full article at the original source below.